PLG
0.018
80%
M2R
0.002
-33.3%
MDI
0.034
70%
DY6
0.215
-28.3%
COD
0.17
54.5%
CTN
0.003
-25%
FBM
0.036
50%
XGLR
0.003
-25%
TMX
0.003
50%
BKT
0.021
-22.2%
TEM
0.007
40%
CTO
0.004
-20%
HMX
0.036
38.5%
QXR
0.004
-20%
IMI
0.011
37.5%
HIQ
0.017
-19%
AUR
0.008
33.3%
ITM
0.053
-17.2%
MEM
0.004
33.3%
1CG
0.01
-16.7%
ODE
0.008
33.3%
MGU
0.01
-16.7%
RNX
0.004
33.3%
14D
0.021
-16%
VRX
0.145
26.1%
IRD
0.027
-15.6%
DUG
1.98
25.3%
WWG
0.135
-15.6%
GMN
0.082
24.2%
8CO
0.03
-14.3%
ZEU
0.021
23.5%
AAU
0.006
-14.3%
IVZ
0.22
22.2%
BNL
0.006
-14.3%
NNL
0.11
22.2%
EM2
0.006
-14.3%
ALM
0.006
20%
ENT
0.006
-14.3%
AMS
0.006
20%
JAY
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NTI Completed patient recruitment for its clinical trial for children with Autism

Neurotech International (ASX:NTI) completed patient recruitment for its Phase II/III NTIASD2 clinical trial for children with Autism. Patients recruited require substantial support and very substantial support autism | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231219/pdf/05yq6fqpsynsvp.pdf #Autism #shorts